Xenglu [Empagliflozin]25mg tablets
₨1,186
Payment Methods:

Description
Xenglu (Empagliflozin 25mg) Tablets
Advanced Blood Sugar Control for Type 2 Diabetes
Xenglu contains Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, designed to help lower blood sugar levels in adults with type 2 diabetes. It works by reducing glucose absorption in the kidneys and promoting its excretion through urine, leading to better glycemic control, weight management, and cardiovascular benefits.
Key Benefits
✔ Effectively Lowers Blood Sugar Levels – Supports diabetes management.
✔ Reduces Risk of Heart & Kidney Disease – Provides cardiovascular and renal protection.
✔ Promotes Weight Loss & Reduces Blood Pressure – Helps in overall metabolic health.
✔ Works Independently of Insulin – Can be used alone or with other diabetes medications.
✔ Once-Daily Dosage – Provides 24-hour glucose control.
How to Use
- Take one tablet daily, or as prescribed by your doctor.
- Swallow whole with water; do not crush or chew.
- Can be taken with or without food.
- Follow a healthy diet and regular exercise routine for best results.
Important Information
- Stay hydrated to prevent dehydration.
- May cause increased urination as part of its glucose-lowering effect.
- Monitor kidney function and blood sugar levels regularly.
- Not recommended for individuals with severe kidney disease.
- Consult your doctor if you experience signs of urinary or genital infections.
Xenglu is a highly effective treatment for type 2 diabetes, helping patients maintain stable blood sugar levels, protect heart and kidney health, and support overall well-being.
Customer Reviews
Related Products
CONTACT DETAILS
- Shop #3,4 Chaudhary Plaza Dhama moor Main adiyala road Rawalpindi
-
03125059372
0515561209 - info@shazeenpharmacy.com
- Customer Support: 7 Days a Week, 10:00AM - 10:00PM
Quick Links
Useful Links
SUBSCRIBE OUR NEWSLETTER
Get the latest offers and promotions!
Copyright © 2025 Shazeen Chemist. All rights reserved.

Reviews
Clear filtersThere are no reviews yet.